Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04608448 · ClinicalTrials.gov registry record · Early Phase 1

Topical-RAPA Use in Inflammation Reversal and Re-setting the Epigenetic Clock

A Early Phase 1 study of Aging and Epigenetics, sponsored by The University of Texas Health Science Center at San Antonio.

Completed
Registry status
Early Phase 1
Development phase
22
Enrollment target
1
Study location

NCT04608448 is a Early Phase 1 study of Aging and Epigenetics that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 22 participants, below the 2,195-participant average among 262 other Aging trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04608448, a Early Phase 1 study of Aging and Epigenetics, has completed, sponsored by The University of Texas Health Science Center at San Antonio.

COMPLETED
Registry status
Early Phase 1
Development phase
22 participants
Enrollment target
1
Study location

Study Summary

Topical Rapamycin ointment will be applied to participant forearms to test whether epigenetic changes in the skin are elicited.

Interventions

  • OTHER Placebo
  • DRUG Rapamycin Topical Ointment

Study Locations (1)

Texas

  • UTHSCSA - San Antonio

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2021-04-28
Est. Completion 2022-04-15
Phase Early Phase 1

What the Registry Record Tells You About NCT04608448

The ClinicalTrials.gov registry entry for NCT04608448 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,195-participant average among 262 other Aging trials with a reported enrollment target (99% lower). The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Aging appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT04608448 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT04608448 about?

NCT04608448 is a clinical study titled "Topical-RAPA Use in Inflammation Reversal and Re-setting the Epigenetic Clock". Topical Rapamycin ointment will be applied to participant forearms to test whether epigenetic changes in the skin are elicited.

What is the current status of trial NCT04608448?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 22 participants. The study started on 2021-04-28. Estimated completion is 2022-04-15.

What conditions does trial NCT04608448 study?

This clinical trial studies the following conditions: Aging, Epigenetics, Inflammatory Mediators.

What interventions are being tested in trial NCT04608448?

The interventions under investigation include: Placebo (OTHER), Rapamycin Topical Ointment (DRUG).

Who is sponsoring clinical trial NCT04608448?

This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04608448 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Aging

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.